The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 23, Issue 8, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-19
DOI
10.1007/s11883-021-00936-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
- (2020) Ulf Landmesser et al. CARDIOVASCULAR RESEARCH
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions
- (2020) Aliza Hussain et al. Current Atherosclerosis Reports
- Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies
- (2020) Julia Brandts et al. CURRENT OPINION IN LIPIDOLOGY
- Prognostic utility of triglyceride-rich lipoproteins-related markers in patients with coronary artery disease
- (2020) Ye-Xuan Cao et al. JOURNAL OF LIPID RESEARCH
- Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
- (2020) Julius L. Katzmann et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy
- (2020) Oluwayemisi Esan et al. Drug Design Development and Therapy
- Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
- (2020) Daniel Gaudet et al. EUROPEAN HEART JOURNAL
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein(a) and Cardiovascular Disease
- (2020) Pia R Kamstrup CLINICAL CHEMISTRY
- Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care
- (2020) Kausik K Ray EUROPEAN HEART JOURNAL
- PCSK9 and atherosclerosis: Looking beyond LDL regulation
- (2020) Rosetta Ragusa et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Evinacumab in Patients with Refractory Hypercholesterolemia
- (2020) Robert S. Rosenson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel strategies to target PCSK9: beyond monoclonal antibodies
- (2019) Nabil G Seidah et al. CARDIOVASCULAR RESEARCH
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Lipid-Lowering Agents
- (2019) Robert A. Hegele et al. CIRCULATION RESEARCH
- Statin therapy increases lipoprotein(a) levels
- (2019) Sotirios Tsimikas et al. EUROPEAN HEART JOURNAL
- Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes
- (2019) Claudia Lamina et al. JAMA Cardiology
- Volanesorsen: First Global Approval
- (2019) Julia Paik et al. DRUGS
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES
- (2019) C. Macchi et al. PHARMACOLOGICAL RESEARCH
- Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis
- (2019) Dirk J. Blom et al. Current Atherosclerosis Reports
- Advances in lipid-lowering therapy through gene-silencing technologies
- (2018) Børge G. Nordestgaard et al. Nature Reviews Cardiology
- Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS)
- (2018) Nicolas Danchin et al. European Journal of Preventive Cardiology
- Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies
- (2018) Stephen Burgess et al. JAMA Cardiology
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inhibiting PCSK9 — biology beyond LDL control
- (2018) Robert M. Stoekenbroek et al. Nature Reviews Endocrinology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
- (2017) Nathan O. Stitziel et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Angiopoietin-like 3 in lipoprotein metabolism
- (2017) Sander Kersten Nature Reviews Endocrinology
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
- (2017) Anastasia Khvorova NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
- (2017) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
- (2016) Yajnavalka Banerjee et al. ATHEROSCLEROSIS
- Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
- (2016) Ozlem Bilen et al. Current Atherosclerosis Reports
- PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
- (2016) Matthew K. Ito et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
- (2016) Nicholas J Viney et al. LANCET
- Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
- (2016) Geesje M. Dallinga-Thie et al. Current Cardiology Reports
- The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
- (2015) Moritz C. Wyler von Ballmoos et al. Journal of Clinical Lipidology
- Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
- (2015) Gregory G. Schwartz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Demographic and Epidemiologic Drivers of Global Cardiovascular Mortality
- (2015) Gregory A. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Triglycerides and cardiovascular disease
- (2014) Børge G Nordestgaard et al. LANCET
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
- (2013) Pia R. Kamstrup et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins
- (2009) Carlos O. Mendivil et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
- (2009) Pia R. Kamstrup JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
- (2009) Robert Clarke et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started